Prospective Plasma Therapy Study, 400 Patients Enrolled
Summary
This study is a prospective, multicenter, real-world observational study conducted across multiple hospitals in China. It will enroll 400 patients receiving plasma device therapy plus standard scar care and compare them with 400 matched patients receiving standard care alone, with follow-up at 6 months. The study evaluates outcomes including Vancouver Scar Scale scores, pain and pruritus relief, scar thickness reduction, and recurrence rates.
“A total of 400 patients receiving standard scar care plus plasma therapy will be enrolled from multiple hospitals across China.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A prospective observational study on plasma therapy for scar management has been registered on ClinicalTrials.gov (NCT07548593). The study will enroll 400 patients in China receiving plasma device therapy plus standard scar care and compare outcomes with 400 matched patients receiving standard care alone, with follow-up at 6 months.
Healthcare providers and clinical investigators conducting scar treatment research should note this registry entry as a reference for ongoing plasma therapy studies. The study's outcomes, including Vancouver Scar Scale scores and recurrence rates, may inform future clinical practice for plasma-based scar treatments.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Plasma Therapy for Scar Management: A Prospective Study
Observational NCT07548593 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard scar care is effective and safe for treating various types of scars, including hypertrophic scars, keloids, atrophic scars, postoperative scars, burn scars, and post-traumatic scars. A total of 400 patients receiving standard scar care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 400 matched patients who received standard scar care alone. The main outcomes include change in Vancouver Scar Scale (VSS) score, pruritus relief, pain relief, scar thickness reduction, patient satisfaction, recurrence rate at 6 months, and any side effects. Patients will be followed for up to 6 months after treatment completion.
Conditions: Wound Healing
Interventions: Plasma Device
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.